HSK29116 / Haisco - LARVOL DELTA

Phase 1 study of HSK29116, a Bruton tyrosine kinase (BTK) proteolysis-targeting chimera (PROTAC) agent, in patients with relapsed or refractory B-cell malignancies (AACR 2023) - P1 | "Exploratory analyses will evaluate the relationship between HSK29116 anti-tumor activity and BTK gene mutations, as well as BTK protein degradation effects of HSK29116 . Descriptive statistics will be used to summarize all data."

Clinical • P1 data • Hematological Malignancies • Oncology • BTK

A Study of HSK29116 in Adults With Relapsed/Refractory B-cell Malignancies (clinicaltrials.gov) - P1 | N=156 | Recruiting | Sponsor: Haisco Pharmaceutical Group Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Chronic Lymphocytic Leukemia • Hematological Malignancies • Oncology • Targeted Protein Degradation